|

Trametinib Clinical Trials

22 actively recruiting trials across 9 locations

▲ +1 trial since June 2026

Also known as: Closed cohort, GSK 1120212, GSK-1120212, GSK1120212, GSK1120212B +6 more

Pipeline

Phase 1: 6Phase 2: 9Phase 3: 1Phase 4: 1Phase 1/2: 4

Top Sponsors

  • Novartis Pharmaceuticals2
  • Bristol-Myers Squibb2
  • Vividion Therapeutics, Inc.1
  • University of California, San Francisco1
  • University Hospital, Strasbourg, France1

Indications

  • Cancer22
  • Lung Cancer3
  • Solid Tumor2
  • High Grade Glioma2
  • Advanced Solid Tumors Harboring the KRAS G12C Mutation1

Other12 trials

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Phase 2
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
Phase 2
Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas
Phase 1
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
Phase 1/2
Imatinib and Trametinib for KRAS-mutated Solid Tumor
Phase 1
Melanoma Metastasized to the Brain and Steroids
Phase 2
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
Phase 2
Precision Cancer Therapy in Rare Cancers
Phase 2
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Phase 1/2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Birmingham, Alabama2 trials

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

UAB Comprehensive Cancer Center

Phase 1/2
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

University of Alabama at Birmingham, Children's of Alabama

Phase 1

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Anchorage, Alaska1 trial

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Anchorage Associates in Radiation Medicine

Phase 3

Phoenix, Arizona1 trial

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phoenix Children's Hospital

Phase 1/2

Scottsdale, Arizona1 trial

Dabrafenib and/or Trametinib Rollover Study

Honor Health Research Institute

Phase 4

Duarte, California1 trial

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

City of Hope Medical Center

Phase 1

Iowa City, Iowa1 trial

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

University of Iowa

Phase 1

Grand Rapids, Michigan1 trial

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

START Mid West

Phase 1

Basking Ridge, New Jersey1 trial

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.